Literature DB >> 26462859

Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?

P Fernandes1, J MacSharry2, T Darby3, A Fanning2, F Shanahan2,4, A Houston2,4, E Brint2,5.   

Abstract

The innate immune system is currently seen as the probable initiator of events which culminate in the development of inflammatory bowel disease (IBD) with Toll-like receptors (TLRs) known to be involved in this disease process. Many regulators of TLRs have been described, and dysregulation of these may also be important in the pathogenesis of IBD. The aim of this study was to perform a co-ordinated analysis of the expression levels of both key intestinal TLRs and their inhibitory proteins in the same IBD cohorts, both ulcerative colitis (UC) and Crohn's disease (CD), in order to evaluate the potential roles of these proteins in the pathogenesis of IBD. Of the six TLRs (TLRs 1, 2, 4, 5, 6 and 9) examined, only TLR-4 was increased significantly in IBD, specifically in active UC. In contrast, differential alterations in expression of TLR inhibitory proteins were observed. A20 and suppressor of cytokine signalling 1 (SOCS1) were increased only in active UC while interleukin-1 receptor-associated kinase 1 (IRAK-m) and B cell lymphoma 3 protein (Bcl-3) were increased in both active UC and CD. In contrast, expression of both peroxisome proliferator-activated receptor gamma (PPARγ) and Toll interacting protein (Tollip) was decreased in both active and inactive UC and CD and at both mRNA and protein levels. In addition, expression of both PPARγ and A20 expression was increased by stimulation of a colonic epithelial cell line Caco-2 with both TLR ligands and commensal bacterial strains. These data suggest that IBD may be associated with distinctive changes in TLR-4 and TLR inhibitory proteins, implying that alterations in these may contribute to the pathogenesis of IBD.
© 2015 British Society for Immunology.

Entities:  

Keywords:  PPARγ; Toll-like receptor; Tollip; inflammatory bowel disease; regulation

Mesh:

Substances:

Year:  2015        PMID: 26462859      PMCID: PMC4750602          DOI: 10.1111/cei.12732

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria.

Authors:  Elizabeth Furrie; Sandra Macfarlane; George Thomson; George T Macfarlane
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

Review 2.  Pattern recognition receptors--molecular orchestrators of inflammation in inflammatory bowel disease.

Authors:  David Walsh; Joanna McCarthy; Caitriona O'Driscoll; Silvia Melgar
Journal:  Cytokine Growth Factor Rev       Date:  2012-10-25       Impact factor: 7.638

Review 3.  Role of commensal gut bacteria in inflammatory bowel diseases.

Authors:  Gunnar Loh; Michael Blaut
Journal:  Gut Microbes       Date:  2012-10-11

4.  Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.

Authors:  Senad Divanovic; Aurelien Trompette; Sowsan F Atabani; Rajat Madan; Douglas T Golenbock; Alberto Visintin; Robert W Finberg; Alexander Tarakhovsky; Stefanie N Vogel; Yasmine Belkaid; Evelyn A Kurt-Jones; Christopher L Karp
Journal:  Nat Immunol       Date:  2005-04-24       Impact factor: 25.606

Review 5.  Barrier-protective function of intestinal epithelial Toll-like receptor 2.

Authors:  E Cario
Journal:  Mucosal Immunol       Date:  2008-11       Impact factor: 7.313

Review 6.  TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization.

Authors:  Cecilia Garlanda; Hans-Joachim Anders; Alberto Mantovani
Journal:  Trends Immunol       Date:  2009-08-21       Impact factor: 16.687

7.  Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family.

Authors:  Cecilia Garlanda; Federica Riva; Tania Veliz; Nadia Polentarutti; Fabio Pasqualini; Enrico Radaelli; Marina Sironi; Manuela Nebuloni; Elisabetta Omodeo Zorini; Eugenio Scanziani; Alberto Mantovani
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

8.  Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis.

Authors:  Lenka Frolova; Pavel Drastich; Pavel Rossmann; Klara Klimesova; Helena Tlaskalova-Hogenova
Journal:  J Histochem Cytochem       Date:  2007-11-26       Impact factor: 2.479

9.  PPARγ in Inflammatory Bowel Disease.

Authors:  Vito Annese; Francesca Rogai; Alessia Settesoldi; Siro Bagnoli
Journal:  PPAR Res       Date:  2012-09-10       Impact factor: 4.964

10.  Transcript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis.

Authors:  Fausto Sánchez-Muñoz; Gabriela Fonseca-Camarillo; Marco A Villeda-Ramírez; Elizabeth Miranda-Pérez; Edgar J Mendivil; Rafael Barreto-Zúñiga; Misael Uribe; Rafael Bojalil; Aarón Domínguez-López; Jesús K Yamamoto-Furusho
Journal:  BMC Gastroenterol       Date:  2011-12-20       Impact factor: 3.067

View more
  22 in total

Review 1.  The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions.

Authors:  Stephen M Vindigni; Timothy L Zisman; David L Suskind; Christopher J Damman
Journal:  Therap Adv Gastroenterol       Date:  2016-04-19       Impact factor: 4.409

Review 2.  Epithelial Toll-like receptors and their role in gut homeostasis and disease.

Authors:  Juan F Burgueño; Maria T Abreu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-26       Impact factor: 46.802

3.  Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells.

Authors:  Mathias Schneider; Thomas Efferth; Heba Abdel-Aziz
Journal:  Front Pharmacol       Date:  2016-10-26       Impact factor: 5.810

4.  Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.

Authors:  Angela C Baird; Dominic Mallon; Graham Radford-Smith; Julien Boyer; Thierry Piche; Susan L Prescott; Ian C Lawrance; Meri K Tulic
Journal:  World J Gastroenterol       Date:  2016-11-07       Impact factor: 5.742

Review 5.  New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Mingxia Zhou; Jing He; Yujie Shen; Cong Zhang; Jiazheng Wang; Yingwei Chen
Journal:  Biomed Res Int       Date:  2017-08-02       Impact factor: 3.411

Review 6.  Growth Hormone Resistance-Special Focus on Inflammatory Bowel Disease.

Authors:  Christoffer Soendergaard; Jonathan A Young; John J Kopchick
Journal:  Int J Mol Sci       Date:  2017-05-09       Impact factor: 5.923

Review 7.  Toll-Interacting Protein in Resolving and Non-Resolving Inflammation.

Authors:  Elizabeth J A Kowalski; Liwu Li
Journal:  Front Immunol       Date:  2017-05-05       Impact factor: 7.561

Review 8.  Toll-interacting protein impacts on inflammation, autophagy, and vacuole trafficking in human disease.

Authors:  Xiaoyun Li; Gillian C Goobie; Yingze Zhang
Journal:  J Mol Med (Berl)       Date:  2020-10-31       Impact factor: 4.599

9.  The Promise of Patient-Derived Colon Organoids to Model Ulcerative Colitis.

Authors:  Babajide A Ojo; Kelli L VanDussen; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2022-02-01       Impact factor: 7.290

10.  An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer.

Authors:  Charlotte O'Donnell; Amr Mahmoud; Jonathan Keane; Carola Murphy; Declan White; Sinead Carey; Micheal O'Riordain; Michael W Bennett; Elizabeth Brint; Aileen Houston
Journal:  Br J Cancer       Date:  2015-12-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.